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Abstract
Platelet-derived growth factor (PDGF) gene therapy offers promise for tissue engineering of tooth-supporting
alveolar bone defects. To date, limited information exists regarding the safety profile and systemic biodis-
tribution of PDGF gene therapy vectors when delivered locally to periodontal osseous defects. The aim of this
preclinical study was to determine the safety profile of adenovirus encoding the PDGF-B gene (AdPDGF-B)
delivered in a collagen matrix to periodontal lesions. Standardized alveolar bone defects were created in rats,
followed by delivery of matrix alone or containing AdPDGF-B at 5.5108 or 5.5109 plaque-forming units=ml.
The regenerative response was confirmed histologically. Gross clinical observations, hematology, and blood
chemistries were monitored to evaluate systemic involvement. Bioluminescence and quantitative polymerase
chain reaction were used to assess vector biodistribution. No significant histopathological changes were noted
during the investigation. Minor alterations in specific hematological and blood chemistries were seen; however,
most parameters were within the normal range for all groups. Bioluminescence analysis revealed vector dis-
tribution at the axillary lymph nodes during the first 2 weeks with subsequent return to baseline levels.
AdPDGF-B was well contained within the localized osseous defect area without viremia or distant organ
involvement. These results indicate that AdPDGF-B delivered in a collagen matrix exhibits acceptable safety
profiles for possible use in human clinical studies.
Introduction
Platelet-derived growth factor (PDGF), a member ofa multifunctional polypeptide family, is composed of
disulfide-bonded A, B, C, or D polypeptide chains to form a
homo- or heterodimeric molecule (Andrae et al., 2008). PDGF
is highly expressed in inflammatory cells, damaged bone,
platelets, and mesenchymal cells (Southwood et al., 2004).
PDGF mediates mitogenesis and chemotaxis of mesenchy-
mal cells and osteoblasts through tyrosine-phosphorylated
signaling pathways (Ronnstrand and Heldin, 2001; Fiedler
et al., 2004). In oral tissues, PDGF also facilitates chemotaxis,
matrix deposition, and attachment of periodontal ligament
cells (Nishimura and Terranova, 1996; Haase et al., 1998).
Delivery of PDGF-BB has also demonstrated enhancement
of periodontal wound repair (Cooke et al., 2006) and re-
generation preclinically (Giannobile et al., 1994, 1996; Park
et al., 2000) and in humans (Howell et al., 1997; Nevins et al.,
2005).
Although exogenous growth factors improve the soft and
hard tissue healing response, more sophisticated delivery
methods are necessary to ensure adequate protein concen-
tration and specific cell targeting to defect sites (Ramseier et al.,
2006; Cotrim and Baum, 2008). Recombinant adenoviruses
(Ads) have been used as gene delivery vectors because of
several unique features: (1) Ads have high transduction effi-
ciency in both dividing and nondividing cells; (2) Ads do
not induce apparent phenotypic changes in transduced cells;
and (3) Ads do not integrate into the host genome and re-
main episomal (Gu et al., 2004). Compared with recombinant
growth factors, adenovirus encoding PDGF gene sequences
(AdPDGF) can successfully transduce cells, prolong growth
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factor expression, and induce downstream signaling path-
ways (Chen and Giannobile, 2002).
Adenoviral vectors administered to the head and neck for
salivary gland repair have been previously studied and are
now in clinical development (Cotrim et al., 2007; Voutetakis
et al., 2008). Matrix-mediated delivery of DNA vectors has
the potential to localize the vector and transgene products
within the immediate delivery site (Chandler et al., 2000). We
have previously shown that AdPDGF-B delivery in colla-
gen significantly improves cementogenesis and osteogenesis
in vivo ( Jin et al., 2004). A preclinical investigation using the
AdPDGF-B=collagen combination in a rabbit dermal wound
model revealed robust localized wound healing responses
with minimal systemic vector dissemination (Gu et al., 2004).
On the basis of our current knowledge, no existing data
describe the systemic effects of adenoviral vector delivered to
the osseous craniofacial complex. In this study we sought to
evaluate the safety profile for the local, collagen matrix-
mediated delivery of AdPDGF-B for the promotion of alveolar
bone healing. Vector copy number and expression at the de-
fect site and various organs were quantified, and systemic
hematology and blood chemistry were evaluated. In combi-
nation with histological findings, the data in the present study
further support the clinical development of matrix-enabled
gene therapy for periodontal wound regeneration.
Materials and Methods
Adenoviral vectors
E1-,E3-deleted human adenovirus serotype 5 vectors en-
coding transgenes under the control of the cytomegalovirus
promoter were employed in this study. Adenovirus encoding
human platelet-derived growth factor-B (AdPDGF-B) and
adenovirus encoding firefly luciferase (AdLuc) were used for
gene transfer. Titers of viral stocks were determined on em-
bryonic kidney 293 cells by plaque assay and expressed as
plaque-forming units (PFU) per milliliter. Two different doses
of adenoviral vectors were examined in this study: 5.5108
and 5.5109 PFU=ml in 20 ml of collagen matrix. These dose
levels were equivalent to AdPDGF-B concentrations previ-
ously described ( Jin et al., 2004).
Preparation of adenovirus gene-activated matrix
AdPDGF-B and AdLuc were dialyzed into GTS buffer
(2.5% glycerol, 25 mM NaCl, 20 mM Tris; pH 8.0) and for-
mulated in bovine fibrillar type I collagen matrix (Matrix
Pharmaceutical, Fremont, CA) to a final concentration of 2.6%.
Periodontal alveolar bone wound model
and AdPDGF-B treatment
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of Michi-
gan (Ann Arbor, MI). A total of 144 (75 male, and 69 female)
10-week-old Sprague-Dawley rats (weighing 250–300 g) were
used in this investigation. The general timeline, grouping cri-
teria, and study design are shown in Fig. 1A and total gender
distributions for each experiment are described separately.
Two different adenovirus gene-activated matrices were
prepared immediately before surgery, containing AdPDGF-B
at 5.5108 PFU=ml (low dose), AdPDGF-B at 5.5109 PFU=ml
(high dose), or collagen matrix alone. For surgical operations,
the animals were anesthetized with ketamine (50 mg=kg) and
xylazine (10 mg=kg), followed by analgesia as needed with
buprenorphine (Buprenex, 0.1–0.5 mg=kg; Reckitt Benckiser
Healthcare, Hull, UK). Standardized 321 mm osseous de-
fects were created in the buccal plate overlying the mandi-
bular first molar and second molar tooth roots as previously
described ( Jin et al., 2003). The exposed roots were carefully
denuded of periodontal ligament, cementum, and superficial
dentin. Twenty microliters of adenovirus=collagen matrix
was then delivered to the defects, filling them to entirety. The
wounds were closed by suturing the superficial musculature
layers and approximating the skin by surgical clips. The rats
received analgesics on the next day as needed for up to 7 days
postsurgery. The animals also received supplemental antibi-
otics (ampicillin, 268mg=liter of dextrose in distilled water) for
7 days. The surgical clips were removed 10 days after surgery.
Six rats without any surgical interventions (no treatment)
were also included to compare the effect on body homeostasis
of the surgical procedure versus no treatment.
Body weight and clinical observations
Twenty-four male rats were distributed equally to four
groups (high-dose AdPDGF-B, low-dose AdPDGF-B, colla-
gen matrix only, and no treatment). The body weight of those
animals was measured during the first 3 weeks. Clinical ob-
servation was focused on evaluation of the gross signs of
swelling and lesions on days 3–35 as noted in Fig. 1A.
Tissue harvesting, and histological
and histopathological observations
On sacrifice, the submandibular lymph nodes, axillary
lymph nodes, brain, lung, heart, liver, spleen, kidney, and
testes (from male rats), and the entire tissue within defect area
as well as ovaries (from female rats), were harvested with
sterile scissors for each of the specific tissues and organs. The
instruments were sterilized between tissue harvests, using a
glass bead sterilizer. The ipsilateral organs were chosen, and
for organs with abundant DNA (heart, lung, liver, spleen,
kidney, sex organs, and brain), sectioning was done at the
center of each specimen. Half of the selected tissues were then
preserved in a 808C freezer for DNA extraction, and the
remaining half were fixed with 10% formalin for 24 hr and
transferred to 75% ethanol for subsequent histological and
histopathological analysis. The defect mandibulae were dec-
alcified with 10% acetic acid, 4% formaldehyde, and 0.85%
NaCl for 3 weeks. Decalcified mandibulae and the organ
specimens were then dehydrated in step gradients of ethanol
and embedded in paraffin. Sections from two different regions
(border and central level of defect) were made in mandibular
samples and three to six slices from the central-cut sections
(5–8mm in thickness). Hematoxylin and eosin staining was
performed on all histological sections, followed by patholog-
ical examination. The time points for analyses were from days
3 to 35 as described in Fig. 1A. A thorough histopathological
examination was performed for all sections.
Kinetics of luciferase expression
by AdLuc=GAM in vivo
Adenovirus encoding luciferase (AdLuc) was formulated
at concentrations of 5.5108 PFU=ml (low dose, n¼ 6, 3 per
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gender) and 5.5109 PFU=ml (high dose, n¼ 6, 3 per gender)
in 20ml of collagen matrix. Luciferase expression within each
of the animals was measured with an in vivo imaging system
(Xenogen=Caliper Life Sciences, Alameda, CA). To standard-
ize the images, the cutoff threshold was set at 5000 p=sec=
cm2=sr to reduce the background signals, and the yield
threshold was set at 13,000 p=sec=cm2=sr. The amplitude of
luciferase expression was calculated by subtracting the in-
tensity of luciferin signal before and 12–15 min after luciferin
(Promega, Madison, WI) injection (4 mg of luciferin per 25 g of
body weight). The time points for evaluation are described in
Fig. 1A.
Hematology and blood chemistry
All procedures were performed by the animal health di-
agnostic laboratory in the Unit for Laboratory Animal Medi-
cine (ULAM) at the University of Michigan. Twenty-four male
rats were distributed equally into four groups (high-dose
AdPDGF-B, low-dose AdPDGF-B, collagen alone, and no
treatment), and blood was drawn from the day before surgery
through 35 days postoperation (Fig. 1A). Fifty microliters of
whole blood from each rat was placed into a tube containing
EDTA anticoagulant for hematological specimens and a
complete blood cell count (CBC) with automatic differential
was performed. Serum (200 ml) was drawn from each animal
and the chemical parameters examined included alkaline
phosphatase, calcium, phosphorus, creatinine kinase, albu-
min, globulin, total protein, blood urea nitrogen (BUN), cre-
atinine, aspartate transaminase (AST), alanine transaminase
(ALT), bilirubin, total bilirubin (T. bilirubin), amylase, glu-
cose, and cholesterol.
Quantitative polymerase chain reaction assay
Quantitative TaqMan polymerase chain reaction (PCR)
was used to determine the vector copy number of AdPDGF-B
in the bloodstream and organs. The primers used for
FIG. 1. General study design and body weight change over time. (A) Five treatment groups (5.5108 PFU=ml
AdLuc=collagen, 5.5109 PFU=ml AdLuc=collagen, 5.5108 PFU=ml AdPDGF-B=collagen, 5.5109 PFU=ml AdPDGF-B=
collagen, and collagen matrix only) were investigated. The observation time points were over a period of 35 days on a weekly
basis; two animals in 5.5109 PFU=ml AdLuc=collagen group were observed for 75 days. Nontreated animals (neither
surgical defect nor adenovirus–collagen mixture application) were also included in the experiment to evaluate systemic
involvement. (B) All the surgically treated animals experienced transient body weight loss in the first few days posttreatment
but thereafter gained weight continuously throughout the study period.
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quantitative real-time PCR (qPCR) bridging the vector back-
bone and PDGF-B prepro region were as follows: sense, 50-
GGATCTTCGAGTCGACAAGCTT-30; antisense, 50-ATCTC
ATAAAGCTCCTCGGGAAT-30; internal fluorogenic probe,
50-CGCCCAGCAGCGATTCATGGTGAT-30. qPCR was per-
formed with TaqMan universal PCR master mix (Applied
Biosystems, Foster City, CA). Briefly, a 30-ml PCR was pre-
pared with 500 ng of DNA and a 1.5-ml mixture of gene
fluorogenic probe and primers. The thermal conditions were
as follows: 508C for 2 min, 958C for 10 min, followed by 45
cycles of 958C for 15 sec and 608C for 1 min, and the resulting
amplicon was detected with an ABI PRISM 7700 sequence
detection instrument (Applied Biosystems). The standard
curve was determined with a range of 101 to 105 AdPDGF-B
particles (regression correlation coefficient, >95%). The pos-
sibility of cross-reactivity was evaluated by adding adenovi-
ral vector encoding PDGF-A, PDGF-1308 (dominant-negative
mutant PDGF), bone morphogenetic protein-7, noggin, bone
sialoprotein, luciferase, and green fluorescent protein (GFP)
for comparison. No enhancement or inhibition of signal was
noted when tissues were spiked with these vectors.
For blood DNA, the samples were collected from 6 rats
per gender (total of 12 per group) in the four groups (high-
dose AdPDGF-B, low-dose AdPDGF-B, collagen matrix
only, and no treatment) before surgery, and throughout 35
days after gene delivery (Fig. 1A). Fifty microliters of whole
blood was isolated and DNA was obtained with a QIAamp
DNA blood mini kit (Qiagen, Valencia, CA). For organ and
tissue DNA, total tissue in the defect area and surrounding
musculature, submandibular lymph node, axillary lymph
nodes, brain, lung, heart, liver, kidney, spleen, and sex or-
gans (testes and ovaries) was excised from three rats in
each of the three groups (high-dose AdPDGF-B, low-dose
AdPDGF-B, and collagen matrix only) postsacrifice, and
triplicate experiments were performed. The time points an-
alyzed were from 3 to 35 days (Fig. 1A). Each PCR contained
500 ng of test DNA without spiking. Prestudy experiments
demonstrated expected signal enhancement with AdPDGF-B
spiking (500 copies per reaction; data not shown). The limit
of detection was 30 copies per 500 ng of test DNA for all the
specimens.
Statistical analysis
Analysis of variance (ANOVA) was used to evaluate the
differences in body weights and hematological and chemical
parameters between experimental and control groups. Test
groups were evaluated for time-dependent dynamics with
collagen and nonsurgical groups, using Bonferroni posttests,
and the significance was assessed by repeated-measures
ANOVA. Results are presented as the mean SD of mea-
surements, with a p value less than 0.05 being considered
statistically significant.
Results
Clinical observations and body weight
All animals survived throughout the entire experimental
period and among all surgically treated animals, no signifi-
cant adverse events were noted beyond local swelling at the
treatment sites, presumably caused by the surgical proce-
dures. Body weight changes were normalized, using day 0 as
baseline, and the measures of weight change were evaluated
as fractions relative to baseline weight. Results showed that
after surgical treatment, all animals experienced slight weight
loss within the first 2 days; however, they consistently gained
weight over the course of the study. No significant weight
changes were found among the three surgical groups at any
time point (Fig. 1B).
Histology and histopathology
Two weeks after surgery, early bone formation could be
observed within the defect area (Fig. 2A, top). Nearly com-
plete bone bridging of the alveolar bone wounds was noted
in both AdPDGF-B-treated groups, whereas there was lim-
ited bridging in the collagen-only animals. Cementogenesis
could be seen in both AdPDGF-B-treated groups at 2 weeks
but not in the collagen matrix group, and the defects treated
with high-dose (5.5109 PFU=ml) AdPDGF-B revealed more
cementum formation compared with the other groups (Fig.
2A, bottom). At 35 days, the bone had completely bridged
all of the defect area, and the fractions of defect fill be-
came consistent in all animals. Animals receiving high-dose
AdPDGF-B demonstrated greater evidence of cementogenesis
along the tooth root (Fig. 2B).
Macroscopic evaluations of the harvested organs revealed
no meaningful changes except mild enlargement of the sub-
mandibular lymph nodes in AdPDGF-B-treated (both high-
dose and low-dose) and collagen matrix-only groups within
the first week postsurgery. Evaluation of histological sections
showed occasional but mild inflammatory infiltration in
lymph nodes, spleen, and liver in all groups. However, no
significant histopathological signs were noted beyond the
suspected alterations associated with the surgical operation.
In particular, no evidence of viral inclusions was observed for
any of the evaluated tissues and organs.
Hematology and blood chemistry
Blood was analyzed from each animal before surgery and
through 35 days postoperation (Fig. 1A). Also, blood from six
animals in the no-treatment group was collected for com-
parison. All parameters for hematology and blood chemistry
were consistent among groups and were generally within the
normal range. Although there were some minor changes, we
found no significant differences in complete blood count
(CBC) and clinical chemistry parameters in any treatment
group throughout the period of observation (Tables 1 and 2).
There were several animals in both the high-dose and low-
dose groups that revealed significant changes in amylase;
however, the majority of the values were within the normal
range. On day 28, animals in the low-dose group demon-
strated significant elevation in serum glucose, but those levels
returned to the baseline range by day 35.
Vector expression by bioluminescence
Whole body image analysis of animals treated with
AdLuc=collagen matrix revealed a transduction and distribu-
tion profile from adenoviral gene delivery over the course of
the experiment. Bioluminescent luciferase expression was de-
tected in the head and neck region for all AdLuc=collagen-
treated animals (n¼ 6 per group), with the level of expression
higher in animals receiving high-dose AdLuc compared with
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the low-dose animals (Fig. 3A). For the low-dose AdLuc-
treated group, luciferase expression gradually decreased to
undetectable levels at the treated sites by 14 days without any
spreading to distant organs for time points thereafter (note in
Fig. 3A whole body imaging [top], some luminescence on day
28 on the animal’s right side). Results also showed gradually
decreasing expression of luciferase in the head and neck region
within 2 weeks in high-dose AdLuc-treated animals. Further,
the high-dose treated animals yielded a weak signal detected
in the axillary lymph node area of three animals, and one
animal showed liver expression at 1 week. However, after
2 weeks no signal was detected in any distant organs of any
animal (Fig. 3B). To further investigate the persistent, low-level
expression of AdLuc signal in two high-dose treated ani-
mals, bioluminescence imaging was performed until sacrifice
at 75 days posttreatment. The defect mandible, surrounding
musculature, axillary lymph nodes, liver, and gonadal organs
were harvested and images were captured for biolumines-
cence quantification. Results revealed that a weak signal was
restricted to only the surrounding musculature (<10 p=sec=
mm2=sr), and no signal was detected in the defect site (data
not shown). In addition, no significant gender differences in
AdLuc expression were revealed; however, a somewhat lower
signal was noted on day 1 in the head and neck region of
female rats receiving high-dose AdLuc treatment ( p< 0.05;
data not shown).
FIG. 2. PDGF gene delivery promotes periodontal tissue regeneration in vivo. (A) Limited bone formation and bridging had
occurred by 14 days in wound treated with collagen matrix only compared with AdPDGF-B=collagen-treated defects. Top:
Original magnification, 40. Bottom: Higher power view (original magnification, 200) of tooth=cementum=periodontal
ligament (PDL)=bone interfaces outlined in red in the top row. More newly formed cementum structure (blue arrows) was
observed in high-dose (5.5109 PFU=ml) AdPDGF-B=collagen-treated sites. (B) At 35 days, defect treated with AdPDGF-B at
5.5109 PFU=ml demonstrated a significant amount of root cementum compared with defect treated with collagen matrix
only. Red arrowheads indicate the edges of exposed tooth dentin surface; blue arrows, new cementum; black asterisks, tooth
roots; yellow asterisks, the area of PDL. (All images are in transverse orientation and stained with hematoxylin and eosin.)







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Biodistribution by quantitative PCR
The specificity of our PCR primers and the sensitivity of the
assay were determined before analysis of the study samples.
We measured no primer cross-reaction with adenovirus en-
coding bone sialoprotein, bone morphogenetic protein-7, lu-
ciferase, noggin, PDGF-A, PDGF-1308, or GFP (data not
shown). The sensitivity and detection limit of our PCR assays
was 30 virus copies per 500 ng of DNA. Within the AdPDGF-
B-treated area, viral vector could be detected within the first
week in DNA from both high-dose and low-dose treated an-
imals. The number of vector copies gradually decreased to
undetectable levels after 2 weeks (Table 3). Vector copies
measured in the blood were below the detection limit for all
animals over the total period of observation. The PCR assay
measured a low level of vector within spleen DNA of one
animal at 3 days posttreatment, and within the lung of another
animal at 2 weeks posttreatment; however, no significant
vector DNA was detected in organs or tissues from the treat-
ment groups for the remainder of the experimental time points
FIG. 3. Vector transduction efficiency and systemic distribution of bioluminescence. (A) Most of the luciferin signal is
restricted to the alveolar bone defect region, with minimal systemic involvement. Signals in distant organs were absent
after 14 days for both dose level groups. (B) Mild vector expression was noted during the first 3–7 days in animals treated
with AdLuc at 5.5108 PFU=ml. (C) Animals treated with AdLuc at 5.5109 PFU=ml demonstrated significant vector
expression during the first 14 days, followed by a decrease in vector expression in the head and neck region over time. The
high-dose group also showed modest vector expression in liver (one of six positive on day 14) and axillary lymph nodes
(one of six positive on day 3, and two of six positive on both days 7 and 10). Group size: n¼ 6 (three per gender). If the
intensity of bioluminescence within the region of interest was less than 5000 p=sec=cm2=sr, that region was defined as
‘‘negative’’.
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(Table 3). These values were below the detection limit and
compared similarly with vector values at the defect site, which
were low to below the detection level. On examination of
histological sections from the tissues (spleen and lung) posi-
tive for AdPDGF-B DNA, we found no inflammation-related
phenotype or other pathological findings when compared
with tissue sections from collagen matrix-treated animals.
Discussion
PDGF-BB protein has demonstrated its strong potential for
soft and hard tissue repair and is available for clinical use
(Nevins et al., 2005; Hollinger et al., 2008). However, because
of the high degradation rate and transient persistence in vivo,
the treatment outcome is not entirely predictable for clinical
applications (Kaigler et al., 2006). Gene delivery using an ad-
enoviral vector provides sustained and stable transduc-
tion efficiency in vitro (Chen and Giannobile, 2002). These
data confirm and extend those of Jin and colleagues (2004)
demonstrating significant enhancement of tooth-supporting
alveolar bone and cementum regeneration in vivo, using gene-
activated matrices containing AdPDGF-B.
Although a number of studies focus on the safety profile of
adenovirus-mediated gene therapy, few of them have ad-
dressed the local delivery of vectors using a gene-activated
matrix and none are related to the periodontium or localized
bone defects. Studies have shown that direct systemic ad-
ministration of adenoviral vectors can result in acute toxicity
and hepatic pathology (Nunes et al., 1999; Lenaerts et al., 2005;
Ni et al., 2005). Systemic dissemination can be reduced and the
efficacy-to-toxicity ratio can be improved by local gene de-
livery (Wang et al., 2005). With localized delivery, the vector
likely enters the systemic circulation via the leaky micro-
vessels and systemically disseminates within 10 min (Wang
et al., 2005), with the inflammatory infiltrate within liver
observed after 15 min in mice (Ni et al., 2005). In this study,
we employed matrix (collagen)-enabled gene delivery for lo-
calized administration to alveolar bone defects. The vector
dissemination in our animals beyond the alveolar bone area
was limited, demonstrating well-contained localization of the
gene-activated matrix.
Studies have shown that nearly 99% of systemically de-
livered adenoviral vectors will eventually accumulate in the
liver, and are rapidly taken up by Kupffer cells and hepato-
cytes (Hackett et al., 2000; Manickan et al., 2006). The Kupffer
cells might distribute to the lung and spleen via the circula-
tion, but in this study we did not detect any significant vector
quantities in those organs. No significant elevation of the
enzymes specific to those organs further demonstrates the
limited systemic influence of this approach. Although trans-
gene luciferase expression was found in the axillary lymph
nodes, spleen, and lungs of a few adenoviral vector-treated
animals at 2 weeks postadministration (with no expression in
these organs at later time points), the level was only slightly
greater than background and no accompanying toxicological
signs or histopathological changes were found. We also noted
no treatment-related toxicity throughout the 35-day period.
Most of the hematological and clinical chemistry parameters
were within normal ranges and the only significant difference
was noted for amylase (derived primarily from the pancreas
and parotid gland, with some from the liver), which is one
of the major enzymes to digest starch into simple sugars.
Changes in serum amylase may represent a normal physio-
logic process, acute or chronic pancreatitis, or concomitant
ongoing diseases (Garrison, 1986). However, lipase is a more
sensitive and specific marker with which to diagnose pan-
creatitis (Tietz et al., 1986), and the lipase level in all of the
animals did not change significantly. However, it is quite
possible that the amylase came from the parotid salivary
gland that was located in close proximity to the surgical field.
The parotid gland in rats is nonencapsulated, as compared
with the gland in humans. We cannot rule out this area at
Table 3. AdPDGF-B PCR Results in Bloodstream and Distant Organs




Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N 3=3 (301) 2=3 (137) 1=3 (84) N N N
5.5109 PFU=ml AdPDGF-B N 3=3 (45,930) 3=3 (6,097) N N N N
Blood Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N N N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Lung Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N 1=3 (38) N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Spleen Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N 1=3 (31) N N N N N





Collagen matrix N N N N N N N
5.5108 PFU=ml AdPDGF-B N N N N N N N
5.5109 PFU=ml AdPDGF-B N N N N N N N
Abbreviations: ALN, axillary lymph nodes; N, negative; PFU, plaque-forming units; SLN, submandibular lymph nodes.
an¼ 3 per group (for organ analyses) and 23 per group (for blood analyses). Test sample DNAs yielding signals below the limit of detection
(<30 vector particles per 500 ng of DNA) are reported as negative. Entries demonstrate ‘‘positive’’ animals in each group and entries in
parentheses indicate the mean vector copy number per 500 ng of DNA from the positive animals.
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early time points. At later time points when we measured the
luciferase signal from the harvested organs, no detectable
signal was found in any of the parotid glands, but mainly
in the surrounding musculature (Fig. 3). In vivo biolumines-
cence generated by expression of the luciferase transgene
permitted quantification and localization of transgene ex-
pression and provided noninvasive, dynamic, and compre-
hensive monitoring of vector expression at the whole body
level (Wood et al., 1999; Johnson et al., 2006). As little as 104
luciferase-expressing recombinant adenoviruses are capable
of producing luminescence in the liver (Honigman et al., 2001),
which is significantly higher in sensitivity than is possible
with qPCR ( Johnson et al., 2006), making bioluminescence a
more sensitive mode of evaluation of biodistribution and
subsequent vector activity. In the early time periods we de-
tected vector in the defect area of adenovirus-treated animals,
which reached undetectable levels by day 14. This result
supports those reported by Jin and colleagues (2004), showing
that the luciferase signal decreased to 20% by day 14 and
reached an undetectable level by day 28 compared with the
expression on day 1. Moreover, given that PDGF is expressed
in vivo over about 10 days in periodontal wounds after injury
(Green et al., 1997), this gene therapy approach demonstrates a
similar expression profile that may be favorable for thera-
peutic application.
In summary, the results of our experiments demonstrate
that local administration of AdPDGF-B with gene-activated
matrix is safe when delivered to tooth-supporting alveo-
lar bone defects. No treatment-related toxicity or systemic in-
volvement was found. Although vector particle DNA was
detectable during the first 2 weeks, primarily in the osseous
defects, the titer was low and quickly attenuated at subsequent
time points. These results support the further clinical devel-
opment of AdPDGF-B for regeneration therapy for oral and
craniofacial bone application.
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